Search results
Results from the WOW.Com Content Network
Boehringer is committed to providing breakthrough therapies for cancer patients, and we look forward to advancing the zongertinib clinical program.” Zongertinib was generally well tolerated for 120 mg and 240 mg, with no deaths attributed to treatment and a low incidence of adverse events leading to dose reductions (11%) and discontinuation (3%).
Novo traded 4% lower on the news Friday. Diabetes drug ... anti-cancer treatment. Ofev: Boehringer Ingelheim's non-small-cell lung cancer treatment. Tradjenta: Boehringer Ingelheim's diabetes drug
Boehringer Ingelheim sued the U.S. government in an attempt to block a program that gives the Medicare health insurance plan the power to negotiate lower drug prices, joining other drugmakers and ...
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one.
Volasertib (also known as BI 6727) is an experimental small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives. [1]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
(Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1, the German drugmaker ...
In December 2017, Boehringer Ingelheim Pharmaceuticals Inc. agreed to pay $13.5 million to settle claims by all 51 state attorneys general (of the 50 states plus the Attorney General of the District of Columbia) that it engaged in off-label promotion of its drugs Aggrenox, Atrovent and Combivent, and Micardis.